Search

Objective: Oral hormone replacement therapy (HRT) has been linked to increased cardiovascular (CVD) morbidity. HRT causes a sustained increase in C-reactive protein (CRP), an excellent marker of subclinical inflammation and CVD. The aim of the study was to support our hypothesis that CRP, which is synthesized in the liver, is not increased in association with transdermal/intrauterine HRT., Material and Methods: A case-control study was performed in which CRP measurements in women receiving levonorgestrel intrauterine system combined with transdermal estradiol (LNG/TDE, n=27) were followed for 9 months or longer. CRP concentrations in these women were compared with those of either oral HRT users (n=20) or controls (n=19)., Results: No significant differences were found in CRP concentrations between the LGN/TDE and control groups (1.8+/-1.2 and 1.8+/-1.8 mg/L, respectively). However, CRP was significantly increased in the oral HRT group (5.5+/-2.9 mg/L, p<0.001)., Conclusions: CRP is significantly increased by oral HRT but not by the LNG/TDE combination after 9 months of treatment. This trend may explain the preponderance of some menopausal women on HRT being at increased risk for the development of CVD. Therefore, the use of LNG/TDE is acceptable for relief of severe climacteric symptoms possibly not imposing an increased CVD risk documented upon oral HRT.

The polycystic ovary syndrome (PCOS), one of the most common reproductive abnormalities, shares some components of the metabolic cardiovascular syndrome. Therefore, PCOS patients may represent the largest group of women at high risk for the development of early-onset cardiovascular disease (CVD) and/or diabetes. C-reactive protein (CRP) is a strong independent predictor of future CVD and/or stroke. Only one small published study has looked for such an association (17 PCOS patients vs. 15 controls). The objective of this study was to compare the levels of CRP and other risk factors of CVD in a large group of PCOS patients and controls. CRP measurements were undertaken in 116 PCOS patients and 94 body mass index-matched controls with regular menstrual cycles. Whereas 36.8% of the PCOS patients had CRP levels above 5 mg/liter, only 9.6% of the controls exhibited high CRP levels (P < 0.001). The mean +/- SD was 5.46 +/- 7.0 in the PCOS group vs. 2.04 +/- 1.9 mg/liter in the control (P < 0.001). The body mass index, white blood cell count, TSH, glucose, cholesterol, and homocysteine levels were not significantly different between the two groups. CRP levels are elevated in patients with PCOS and may be a marker of early cardiovascular risk in these patients. High CRP levels may explain why some PCOS women may possibly be at an increased risk for the development of early-onset CVD. Consequently, whether treatment regimens directed toward lowering CVD risk factors should be more aggressive for those PCOS women with increased CRP levels, awaits further clinical experience.

In order to determine a policy within the hospital restricting smoking we previously surveyed the attitude of the hospital staff towards smoking inside the hospital buildings. In the present survey we examined the attitude of the hospital visitors on the same issue. One hundred and fifty-seven hospital visitors participated in the survey and answered a questionnaire; 93 visitors were smokers, 64 were non-smokers. Eighty-eighth percent of the visitors smoked during their visit, 4 cigarettes on the average, during an average length of stay of 2.8 hours, until completing the questionnaire. Eighty-three percent of the smokers were aware of the law that prohibits smoking in public buildings, and 71% were aware of the signs and advertisements that prohibit smoking in the hospital. Two thirds of the smokers declared that they would have refrained from smoking in the hospital if others around them also refrained from smoking and justified the law that prohibits smoking in public buildings, including hospitals. Sixty-nine percent of the smokers declared that they were willing to cooperate with hospital management in restricting smoking to the hospital grounds outside the hospital buildings, and would accept directives regarding smoking restriction from any hospital personnel. In fact, only 11% of the smokers were requested to stop smoking during their visit. These findings reinforce the results of our pervious survey conducted among the hospital staff and indicates the existence of a paradoxical vicious cycle of behavior among smokers and non-smokers, visitors and staff, in the hospital. On the one hand the smokers do not have the self-obedience necessary to stop smoking while visiting in the hospital, although they are aware of their misdeed. On the other hand the non-smokers lack the confidence that they will obtain the cooperation of the smokers, although the smokers are willing to cooperate. Both groups except someone else to either actively restrict them from smoking or to encourage them to restrict the smokers. Our findings suggest that this "someone else" is the hospital management (and the staff endorsed to implement this directive).

The incidence of all diagnosed cases of familial dysautonomia in Israel among Ashkenazi Jews from 1977-1981 was 27/100,000 or 1/3703. This incidence is higher than that previously reported in Israel in 1967 or 8.3/100,000 (1/12,048) (Moses et al. 1967). It is also higher than that of North American Ashkenazi Jews in 1970, when the rate was 5-10/100,000 (1/10,000-20,000) (Brunt & McKusick 1970). This higher incidence could be explained by current awareness of the diagnosis, or by the emergence of more cases.